Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
Question
Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
Direct answer
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention. — bullish pressure on JNJ.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-28
- Revision
- 1 · 2026-10-29
Cite as: Market Ontology, “Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/johnson-johnson-reports-77-response-rate-in-phase-1b-2-rybrevant-study-14e588
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JNJ | ▲Bull | 1–4 weeks | Macro Repricing | 75 |
Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant study
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention. — bullish pressure on JNJ.
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention.
- SummaryJohnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin for first-line advanced head and neck squamous cell carcinoma. The combination yielded a 77% overall response rate among treated patients. The trial targets non-HPV related presentations of HNSCC, an aggressive subcategory with limited durable frontline options. Confirmation of clinical efficacy in subcutaneous delivery also supports easier administration compared to intravenous alternatives, strengthening franchise retention.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullish | 266.30 2026-10-26 | Pending | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer TrialJNJ
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.